Skip to main content

MSD and Isomorphic Labs announce oncology drug-discovery collaboration

20 NOVEMBER 2026·2 MIN READ·4 SOURCES

MSD and Isomorphic Labs announced a research collaboration on Nov. 19, 2026, to seek small-molecule candidates against one oncology target. The companies have not disclosed the target’s identity.

Key takeaways · 4

  • 01

    The collaboration focuses on small-molecule candidates for one oncology target, whose identity has not been disclosed.

  • 02

    Isomorphic Labs will provide computational predictions and molecular designs; MSD will provide selected proprietary datasets.

  • 03

    MSD will handle preclinical and clinical development, manufacturing and commercialization for products arising from the collaboration.

  • 04

    Isomorphic Labs may receive milestone payments and tiered royalties, and can opt to co-fund development for elevated royalties.

One target, undisclosed

The companies say they will seek therapeutic small-molecule candidates against a single oncology target they describe as strategically important.[1] They have not identified that target publicly.[2] The announcement therefore establishes the scope of the research effort but does not let outside observers assess the target’s biology or compare it with other oncology programs. The companies say the work is intended to find new ways to design and create better candidates faster, and to benefit patient populations with unmet needs.[1]

A division of research work

Isomorphic Labs says its IsoDDE drug-design engine consists of foundational AI models and is modality-agnostic.[1] Under the collaboration, the company will use IsoDDE to make computational predictions and deliver molecular designs.[1] MSD will supply selected high-quality proprietary datasets.[1] MSD says successful AI/ML-based molecular invention depends on close coordination between wet-lab and dry-lab functions.[1] The announced roles point to a partnership that combines computational design with datasets supplied by MSD, rather than placing all research work with one partner.

Development and deal structure

MSD will handle preclinical and clinical development, manufacturing and commercialization of products arising from the collaboration.[1] Isomorphic Labs will receive an upfront payment and may earn additional payments for specified research, development, regulatory and commercial milestones.[1] The agreement also provides for tiered royalties on net sales.[1] Isomorphic Labs can choose to co-fund development activities in return for elevated royalties.[1] The announcement describes these components but provides no payment amounts in the evidence available here.

Company and timing context

MSD is the trade name Merck & Co. uses outside the United States and Canada.[3] The event occurred two days after an announcement of a $5 billion Series C.[4] Separately, Isomorphic Labs has said that, by its own benchmarking, IsoDDE more than doubled AlphaFold 3’s accuracy.[4] That comparison is the company’s own benchmark claim; it does not identify the oncology target or establish the outcome of this collaboration.

The agreement sets out a clear division between AI-generated design work and the datasets and development capabilities MSD will bring. For professionals assessing AI drug-discovery partnerships, the undisclosed target and the milestone- and royalty-based structure are important limits on what can be judged from the announcement alone.

Why it matters
For teams

AI training for your team

kju.ai is built for teams: daily sessions, team analytics, and rollout support for your organization.

How this developed

  1. 20 November 2026

    MSD and Isomorphic Labs announce oncology drug-discovery collaboration

Sources

AI fluency, one session a day, built for your work.